ストックスクリーナーアプリを入手
22.38
0.27%
0.06
アフターアワーズ：
22.38
前日終値:
$22.32
開ける：
$23.0002
24時間の取引高:
726
Relative Volume:
0.20
時価総額：
$2.08B
収益：
$54.07M
当期純損益:
$-160.64M
株価収益率:
-11.12
EPS:
-2.0128
ネットキャッシュフロー:
$-37.25M
1週間 パフォーマンス:
-6.94%
1か月 パフォーマンス:
-10.66%
6か月 パフォーマンス:
-40.84%
1年 パフォーマンス:
+21.24%
1日の値動き範囲:
$22.38
$23.00
1週間の範囲:
$19.11
$23.00
52週間の値動き範囲:
$17.55
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Compare AAPG vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
22.38 | 2.07B | 54.07M | -160.64M | -37.25M | -2.0128 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2026-01-13 | 開始されました | Rodman & Renshaw | Buy |
| 2025-12-04 | 開始されました | Oppenheimer | Outperform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-10 | 開始されました | BTIG Research | Buy |
| 2025-11-05 | 開始されました | Piper Sandler | Overweight |
| 2025-03-27 | 開始されました | JP Morgan | Overweight |
すべてを表示
Ascentage Pharma Group International Adr (AAPG) 最新ニュース
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates - GlobeNewswire Inc.
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3%Should You Buy? - MarketBeat
Short Interest in Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Increases By 546.9% - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownTime to Sell? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 7.7%Here's Why - MarketBeat
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 - Sahm
Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend - TipRanks
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update - The Globe and Mail
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Irhythm Technologies (IRTC) - The Globe and Mail
Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences - TipRanks
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz
Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - TipRanks
Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - markets.businessinsider.com
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail
LENZ Therapeutics (LENZ) Receives a Buy from Piper Sandler - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial - TipRanks
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat
Ascentage Pharma Group International Adr (AAPG) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):